ROCHE HOLDING AG-BR (1RO.MI) Stock Price & Overview

BIT:1RO • CH0012032113

Current stock price

339.6 EUR
-10.4 (-2.97%)
Last:

The current stock price of 1RO.MI is 339.6 EUR. Today 1RO.MI is down by -2.97%.

1RO.MI Key Statistics

Market Cap
274.821B
P/E
15.97
Fwd P/E
15.50
EPS (TTM)
21.27
Dividend Yield
3.13%

1RO.MI Stock Performance

Today
-2.97%
1 Week
-16.35%
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1RO.MI Stock Chart

ROCHE HOLDING AG-BR / 1RO Daily stock chart

1RO.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1RO.MI.


Chartmill TA Rating
Chartmill Setup Rating

1RO.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1RO.MI. 1RO.MI scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1RO.MI Earnings

On January 29, 2026 1RO.MI reported an EPS of 8.53 and a revenue of 30.57B. The company missed EPS expectations (-3.53% surprise) and missed revenue expectations (-3.25% surprise).

Next Earnings DateApr 23, 2026
Last Earnings DateJan 29, 2026
PeriodQ4 / 2025
EPS ReportedCHF8.53
Revenue Reported30.572B
EPS Surprise -3.53%
Revenue Surprise -3.25%

1RO.MI Forecast & Estimates

27 analysts have analysed 1RO.MI and the average price target is 409.71 EUR. This implies a price increase of 20.65% is expected in the next year compared to the current price of 339.6.

For the next year, analysts expect an EPS growth of 3.06% and a revenue growth 1.14% for 1RO.MI


Analysts
Analysts70.37
Price Target409.71 (20.64%)
EPS Next Y3.06%
Revenue Next Year1.14%

1RO.MI Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

1RO.MI Financial Highlights

Over the last trailing twelve months 1RO.MI reported a non-GAAP Earnings per Share(EPS) of 21.27. The EPS increased by 4.41% compared to the year before.


Income Statements
Revenue(TTM)61.52B
Net Income(TTM)12.88B
Industry RankSector Rank
PM (TTM) 20.94%
ROA 12.79%
ROE 38.1%
Debt/Equity 0.85
Chartmill High Growth Momentum
EPS Q2Q%-0.47%
Sales Q2Q%-0.24%
EPS 1Y (TTM)4.41%
Revenue 1Y (TTM)1.69%

1RO.MI Ownership

Ownership
Inst Owners41.71%
Shares809.25M
Float688.92M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About 1RO.MI

Company Profile

1RO logo image Roche Holding AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. Roche Holding AG (Roche) is a research-based healthcare company. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Company Info

IPO: 2001-05-04

ROCHE HOLDING AG-BR

Grenzacherstr. 124

Basel BASEL-STADT CH

Employees: 112774

1RO Company Website

1RO Investor Relations

Phone: 41616881111

ROCHE HOLDING AG-BR / 1RO.MI FAQ

Can you describe the business of ROCHE HOLDING AG-BR?

Roche Holding AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. Roche Holding AG (Roche) is a research-based healthcare company. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.


What is the current price of 1RO stock?

The current stock price of 1RO.MI is 339.6 EUR. The price decreased by -2.97% in the last trading session.


What is the dividend status of ROCHE HOLDING AG-BR?

ROCHE HOLDING AG-BR (1RO.MI) has a dividend yield of 3.13%. The yearly dividend amount is currently 0.


How is the ChartMill rating for ROCHE HOLDING AG-BR?

1RO.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the PE ratio for 1RO stock?

The PE ratio for ROCHE HOLDING AG-BR (1RO.MI) is 15.97. This is based on the reported non-GAAP earnings per share of 21.27 and the current share price of 339.6 EUR.


Should I buy 1RO stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1RO.MI.


Can you provide the ownership details for 1RO stock?

You can find the ownership structure of ROCHE HOLDING AG-BR (1RO.MI) on the Ownership tab.